Acumen Pharmaceuticals, Inc.
ABOS
$2.72
$0.041.49%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -63.83M | 21.97M | 37.13M | 25.27M | 34.57M |
| Gross Profit | 63.83M | -21.97M | -37.13M | -25.27M | -34.57M |
| SG&A Expenses | 4.67M | 4.55M | 4.63M | 5.10M | 5.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.20M | 26.51M | 41.75M | 30.37M | 39.60M |
| Operating Income | -25.20M | -26.51M | -41.75M | -30.37M | -39.60M |
| Income Before Tax | -25.14M | -26.45M | -40.95M | -28.80M | -37.15M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.14M | -26.45M | -40.95M | -28.80M | -37.15M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.14M | -26.45M | -40.95M | -28.80M | -37.15M |
| EBIT | -25.20M | -26.51M | -41.75M | -30.37M | -39.60M |
| EBITDA | -25.19M | -26.50M | -41.73M | -30.36M | -39.58M |
| EPS Basic | -0.42 | -0.44 | -0.68 | -0.48 | -0.62 |
| Normalized Basic EPS | -0.26 | -0.27 | -0.42 | -0.30 | -0.39 |
| EPS Diluted | -0.42 | -0.44 | -0.68 | -0.48 | -0.62 |
| Normalized Diluted EPS | -0.26 | -0.27 | -0.42 | -0.30 | -0.39 |
| Average Basic Shares Outstanding | 60.57M | 60.57M | 60.57M | 60.53M | 60.08M |
| Average Diluted Shares Outstanding | 60.57M | 60.57M | 60.57M | 60.53M | 60.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |